Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 23, 2019
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - January 23, 2019

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/18 - $100mn earmarked for production of 2 new vaccines [Tehran Times (Iran)]
The Office of Biological Products has received $100 million to fund the production of two new vaccines as recommended by the World Health Organization. The head of the Office of Biological Products at Irans Food and Drug Administration, Ali Vasheghani, said the World Health Organization has recommended Iran to put the production of two new vaccines
12/31/18 - 2018 We cartooned on these! [China Daily: Africa Weekly]
On July 15, vaccine producer Changchun Changsheng was revealed to have fabricated the production records for its rabies vaccine, then an early report showing it had produced substandard DTP vaccine for children in 2017 went viral again, which led to public anger.
12/31/18 - 2018 We cartooned on these! [China Daily: US Edition]
On July 15, vaccine producer Changchun Changsheng was revealed to have fabricated the production records for its rabies vaccine, then an early report showing it had produced substandard DTP vaccine for children in 2017 went viral again, which led to public anger.
12/31/18 - Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today announced that the two Phase 3 TRILOGY trials have now exceeded 65% patient randomization, and more than 100 patients have completed their
12/31/18 - Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
Adamis Pharmaceuticals Corporation today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe product candidate. This injection is designed for the treatment of an opioid overdose. Dennis J. Carlo, President and CEO of Adamis, stated, This NDA submission rep
12/31/18 - Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet
SAN DIEGO- Adamis Pharmaceuticals Corporation today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for its fast-dissolving sublingual tadalafil tablet. This product candidate is designed for the treatment of erectile dysfunction. Dennis J. Carlo, President and Chief Executive Officer of Adamis, stated,'
12/31/18 - AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country [Syrian Arab News Agency]
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that, having previously signed a Letter of Intent, a definitive agreement to license.
12/31/18 - Alder BioPharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder s president and chief executive officer, will provide a business overview and update at the 37 th Annual J.P. Morgan Healthcare Conference at 8:00 am PT on Tuesday,
12/31/18 - Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that management will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference onMonday, January 7, 2019 at 10:30 am PT at The Westin St. A replay will be available on the Alnylam website within 48 hours after the event. Alnylam's
12/31/18 - Aralez Pharmaceuticals Completes Sale of Vimovo Royalties and Canadian Operations to Nuvo Pharmaceuticals
-Aralez Pharmaceuticals Inc. announced today that it and certain of its affiliates have completed the previously announced sale of its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals Inc. and Nuvo Pharmaceuticals Designated Activity Company in transactions valued at U.S. The Ontario Superior Court of Justice and the U.S. Bankrup
12/31/18 - Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy M&A deals and several breakthrough developments in drug discovery and research. The FDA on July 9 announced its acceptance of the NDA with priority review status, implying a six-month review period, renderi
12/31/18 - China Jo-Jo Drugstores Announces Strategic Transformation Plan
China Jo-Jo Drugstores, Inc., a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider in China, today announced that the Company is initiating a strategic transformation plan proposed by Mr. Wei Hu, Chief Operating Officer of Jo-Jo Drugstores. The Company expects to
12/31/18 - CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
SEATTLE- CTI BioPharma Corp. announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. These forward-looking statements include statements regarding our expectations regarding anticipated interactions with regulators, our ability to establish a dose for our randomized Phase 3 study of pacritinib, t
12/31/18 - Earth Science Tech, Inc. (ETST) Celebrates A Year of Major Achievements and Shares its Position for a Pivotal 2019
Earth Science Tech, Inc., an innovative biotech company focused on the cannabidiol, nutraceutical and pharmaceutical fields, medical devices, and research and development, reviews the Company s 2018 achievements and shares what s to come in 2019.. During the fiscal first quarter, the Company expanded its executive team with the appointment
12/31/18 - Endo Announces Anticipated Further Stay of Compounding Litigation Due to Lapse of Government Appropriations
Endo International plc today announced that, due to the ongoing federal government shutdown, the U.S. Food and Drug Administration has requested a further stay of Endo's ongoing litigation against the FDA for the duration of the shutdown. That litigation challenges the FDA's authorization of the bulk compounding of drugs, including vasopressin, t
12/31/18 - Enzychem Lifesciences To Present At Biotech Showcase? 2019 In San Francisco
Enzychem Lifesciences, Corp. is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs. Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand...
12/31/18 - Expired drugs latest crisis in Zimbabwe health sector
Zimbabwe's National Pharmaceutical Company accused of tempering with expired drugs for patientsfrom MARCUS MUSHONGA in Harare, ZimbabweHARARE, THE lives of Zimbabwean patients are seemingly in danger amid reports by striking doctors that some medication kept by government as stock have expired.In addition, the government has reportedly failed to...
12/31/18 - FDA approves treatmentfor Parkinson's symptom FDA approves focused ultrasound to treat symptom of Parkinson's
The Food and Drug Administration has approved focused ultrasound as a treatment for a symptom of Parkinson's disease, opening up the pioneering treatment for widespread use. Studies at the University of Virginia, which partners with the Charlottesville- based Focused Ultrasound Foundation, laid the groundwork for the approval. The approval was base
12/31/18 - FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration has accepted the new drug application for Heron's investigational agent, HTX-011,
12/31/18 - Global Intracranial Pressure Monitoring Devices Market 2019-2023| Increase in Regulatory Approvals for Products Impacting Market Growth| Technavio
The global intracranial pressure monitoring devices market 2019-2023 is expected to post a CAGR of close to 7% during the forecast period, according to the latest market research report by Technavio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181231005080/en/.
12/31/18 - GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW s Chief Executive Officer, will present a company update at the J.P. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc..
12/31/18 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 61642) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss new drug application 210934 for sotagliflozin oral tablet, sponsored by Sanofi-Aventis U.S. LLC, for the proposed indication: Adjunct to insulin therapy to improve glycemic control in adul
12/31/18 - Heron Therapeutics, Inc. (NASDAQ:HRTX) Files An 8-K Financial Statements and Exhibits
Heron Therapeutics, Inc. (NASDAQ:HRTX) Files An 8-K Financial Statements and ExhibitsItem 9.01 HERON THERAPEUTICS, INC. /DE/ ExhibitEX-99.1 2 d675951dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FDA Grants Priority Review Designation for Heron Therapeutics? NDA for HTX-011,?To view the full exhibit click here About Heron Therapeutics, Inc. (NASDAQ:HRT
12/31/18 - HERON THERAPEUTICS, INC. /DE/ FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On December 31, 2018, Heron Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration accepted for review, and granted a Priority Review designation for, the Company's New Drug Application for the investigational agent HTX-011, a long-acting, extended-release formulation of the local anesthetic bupivacaine in a
12/31/18 - How Sen. Orrin Hatch Shaped America's Health Care In Controversial Ways
Orrin Hatch, a Utah Republican retiring from 42 years in the Senate as a new generation is sworn in, leaves a long list of achievements in health care. And in 1995, when many people with AIDS were still feeling marginalized by society and elected leaders, he testified before the Senate about reauthorizing funding for his Ryan White CARE Act to trea
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415